Terns Pharmaceuticals Inc (TERN)
5.79
+0.35
(+6.43%)
USD |
NASDAQ |
May 06, 16:00
5.79
0.00 (0.00%)
After-Hours: 19:23
Terns Pharmaceuticals Cash from Financing (TTM): 41.95M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 41.95M |
| September 30, 2023 | 134.06M |
| June 30, 2023 | 195.04M |
| March 31, 2023 | 194.68M |
| December 31, 2022 | 167.10M |
| September 30, 2022 | 61.14M |
| June 30, 2022 | 0.937M |
| Date | Value |
|---|---|
| March 31, 2022 | -0.776M |
| December 31, 2021 | 134.39M |
| September 30, 2021 | 203.02M |
| June 30, 2021 | 202.25M |
| March 31, 2021 | 220.72M |
| December 31, 2020 | 85.52M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-0.776M
Minimum
Mar 2022
220.72M
Maximum
Mar 2021
126.16M
Average
134.39M
Median
Dec 2021
Cash from Financing (TTM) Benchmarks
| Viking Therapeutics Inc | 873.23M |
| Eli Lilly and Co | 2.772B |
| Pfizer Inc | 26.07B |
| Amgen Inc | -2.169B |
| Madrigal Pharmaceuticals Inc | 595.12M |